Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Eisai Creates Oncology Area Department
April 12, 2010
- Banyu Applies for Rotavirus Vaccine
April 12, 2010
- Teijin Pharma Licenses TMX-67 to Astellas in China, Hong Kong
April 12, 2010
- Terumo Creates Diabetes Company Aiming at Top Share
April 12, 2010
- GSK's Revolade Approved for Chronic ITP in Europe
April 12, 2010
- Colon Cancer, Center of Attention in Oncology Market in 2010: Dr Gochenauer of Kantar Health
April 12, 2010
- GSK Becomes JCR's Leading Shareholder
April 12, 2010
- Ciprofloxacin DPI Granted Orphan Drug Status in the US
April 12, 2010
- Asahi Kasei Licenses AK138 Series of Compounds to Altheos
April 12, 2010
- JGA to Suspend Taiyo's Membership for 1 Year
April 12, 2010
- District Court Rules in Favor of Prohibition of Online Sale of Classes 1, 2 OTC Drugs
April 12, 2010
- ASKA Licenses Rifaximin from Alfa Wassermann
April 12, 2010
- President Aratani to Step Down at Taiyo
April 12, 2010
- 83rd Annual Meeting of the Japanese Pharmacological Society
April 12, 2010
- Takeda to Comarket Galantamine with Janssen
April 12, 2010
- FFP Starts Marketing 178 Products with 30 MRs
April 12, 2010
- US Law to Require Companies to Disclose Payments to Physicians
April 12, 2010
- Dr Kondo Reappointed PMDA Chief Executive
April 5, 2010
- Erbitux Approved for Use in First-Line Therapy
April 5, 2010
- NovoSeven Approved for Bleeding in Congenial FVII Deficiency Patients
April 5, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…